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Introduction
Yellow fever virus (YFV), a mosquito-borne flavivirus, is pres-
ent in tropical areas of Africa and South America. In humans, 
the majority of YFV infections are asymptomatic. Clinical 
disease varies from a mild, undifferentiated febrile illness to 
severe disease with jaundice and hemorrhagic manifestations 
(1). After an incubation period of 3–6 days, symptomatic 
yellow fever (YF) infections typically manifest with an abrupt 
onset of fever and headache (2). As the illness progresses, other 
symptoms might occur, including photophobia, myalgias, 
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Summary
This report updates CDC’s recommendations for using yellow fever (YF) vaccine (CDC. Yellow fever vaccine: recommendations 
of the Advisory Committee on Immunizations Practices: MMWR 2002;51[No. RR-17]). Since the previous YF vaccine recom-
mendations were published in 2002, new or additional information has become available on the epidemiology of YF, safety profile 
of the vaccine, and health regulations related to the vaccine. This report summarizes the current epidemiology of YF, describes 
immunogenicity and safety data for the YF vaccine, and provides recommendations for the use of YF vaccine among travelers and 
laboratory workers.
YF is a vectorborne disease resulting from the transmission of yellow fever virus (YFV) to a human from the bite of an infected 
mosquito. It is endemic to sub-Saharan Africa and tropical South America and is estimated to cause 200,000 cases of clinical 
disease and 30,000 deaths annually. Infection in humans is capable of producing hemorrhagic fever and is fatal in 20%–50% 
of persons with severe disease. Because no treatment exists for YF disease, prevention is critical to lower disease risk and mortality. 
A traveler’s risk for acquiring YFV is determined by multiple factors, including immunization status, location of travel, season, 
duration of exposure, occupational and recreational activities while traveling, and local rate of virus transmission at the time of 
travel.
All travelers to countries in which YF is endemic should be advised of the risks for contracting the disease and available methods 
to prevent it, including use of personal protective measures and receipt of vaccine. Administration of YF vaccine is recommended 
for persons aged ≥9 months who are traveling to or living in areas of South America and Africa in which a risk exists for YFV 
transmission. Because serious adverse events can occur following YF vaccine administration, health-care providers should vaccinate 
only persons who are at risk for exposure to YFV or who require proof of vaccination for country entry. To minimize the risk for 
serious adverse events, health-care providers should observe the contraindications, consider the precautions to vaccination before 
administering vaccine, and issue a medical waiver if indicated.
arthalgias, epigastric pain, anorexia, vomiting, and jaundice 
(3,4). In some persons, multisystem organ failure with hem-
orrhagic signs and symptoms occurs. The case-fatality ratio of 
severe yellow fever with hepatorenal dysfunction is 20%–50% 
(1). Because no specific antiviral treatment exists for YF, preven-
tion is critical to lower disease risk and mortality.
YFV has three transmissiotn cycles: jungle (sylvatic), inter-
mediate (savannah), and urban (5). All cycles involve the trans-
mission of YFV between primates (nonhuman or human) and 
mosquitoes. Depending on the transmission cycle and location, 
different mosquito species are involved, and humans or nonhu-
man primates serve as the primary reservoir of the virus.
The World Health Organization (WHO) estimates that 
YFV causes 200,000 cases of clinical disease and 30,000 deaths 
each year (6). However, the majority of cases and deaths are 
not recognized because of the predominantly rural nature of 
the disease and inadequate surveillance and reporting (4,7). In 
recent decades, hundreds of cases have been reported annually 
in South America, primarily among men with occupational 
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exposures in forested areas (8). In Africa, the number of cases 
reported from the continent annually varies substantially 
(range: 1–5,000 cases). Most of the fluctuation in the annual 
case numbers from Africa likely is attributable to variations 
in reporting and recognition. However, because the natural 
occurrence of disease also can fluctuate, being absent in certain 
areas for years before reappearing, delineation of affected areas 
depends on surveillance for animal reservoirs and vectors, accu-
rate diagnosis, and prompt reporting of all human cases.
Evaluation of a traveler’s risk should take into account the 
traveler’s immunization status and planned itinerary, including 
location of travel, season, duration of exposure, occupational 
and recreational activities, and local rate of virus transmission 
at the time of travel. All travelers should be provided advice on 
prevention of mosquito bites. Health-care providers weighing 
a decision as to whether to administer YF vaccine to travelers 
must take into account multiple factors (e.g., the risk for travel-
associated YFV disease, the high morbidity and mortality when 
YF does occur, country-entry requirements for YF vaccine, and 
the risk for serious adverse events following vaccination). This 
report provides recommendations for use of YF vaccine for 
prevention of YF among travelers and laboratory workers.
Methods
The Advisory Committee on Immunization Practices (ACIP) 
Yellow Fever Vaccine Work Group* (the ACIP Work Group) 
first met in September 2008 to review available information 
on the risk for YF for travelers and to revise recommendations 
for the use of the vaccine. In addition to ACIP members, the 
ACIP Work Group included participants from the American 
Academy of Family Physicians, CDC, the U.S. Department 
of Defense, the U.S. Department of State, the Food and 
Drug Administration (FDA), the Infectious Diseases Society 
of America, the International Society of Travel Medicine, the 
Public Health Agency of Canada (PHAC), Boston Medical 
Center, and the Harvard School of Public Health.
Issues reviewed and considered by the ACIP Work Group 
included YF epidemiology; incidence of and risk factors for 
travel-associated YF disease; measures available to prevent YF 
disease; and YF vaccine immunogenicity, safety, and incidence 
of vaccine adverse events. Further consideration was given to 
potential contraindications and precautions to the use of YF 
vaccine and International Health Regulations (IHRs) for the 
vaccine. Published, peer-reviewed studies were the primary 
source of data used. Articles were identified through searches of 
the PubMed, Global Health, and EMBASE databases; review 
of relevant bibliographies; and consultation with subject-matter 
experts. When relevant to issues under discussion, unpublished 
data available at CDC also were considered.
The ACIP Work Group held monthly conference calls until 
May 2009. Recommendation options were developed and 
discussed by the Work Group. When evidence from clinical 
trials or other research studies was lacking, the recommenda-
tions incorporated expert opinion of the ACIP Work Group 
members. A short overview presentation was made to ACIP 
at the June 2009 meeting. Proposed recommendations and a 
draft statement were presented to ACIP and approved at the 
October 2009 meeting.
Background
Yellow Fever Virus transmission
YFV is a ribonucleic acid (RNA) virus that belongs to the 
genus Flavivirus. It is related antigenically to West Nile virus, 
St. Louis encephalitis virus, and Japanese encephalitis virus 
(9). YFV is transmitted to humans primarily through the bite 
of an infected Aedes or Haemagogus species mosquito (10–14). 
Mosquitoes acquire the virus by feeding on infected nonhuman 
or human primates and then can transmit the virus to naïve 
nonhuman or human primates.
YFV has three transmission cycles: jungle (sylvatic), inter-
mediate (savannah), and urban (5) (Figure 1). The jungle 
(sylvatic) cycle involves transmission of the virus between 
nonhuman primates (e.g., monkeys) and tree-hole–breeding 
mosquito species found in the forest canopy (15). The virus 
is transmitted via mosquitoes from monkey to human when 
the humans encroach into the jungle during occupational or 
recreational activities. In Africa, an intermediate (savannah) 
cycle exists that involves transmission of the YFV from tree-
hole–breeding Aedes spp. to humans living or working in jungle 
border areas (16,17). In this cycle, the virus can be transmitted 
from monkey to human or from human to human via these 
mosquitoes. The urban cycle involves anthroponotic trans-
mission of the virus between humans and urban mosquitoes, 
primarily Ae. aegypti.
Humans infected with YFV experience the highest levels of 
viremia and are infectious to mosquitoes shortly before the 
onset of fever and for 3–5 days thereafter (18). Given the high 
level of viremia attained in humans, bloodborne transmission 
theoretically could occur through transfusions or needlestick 
injuries.
* A list of the members of the work group appears on page 27 of this report.
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FIGURE 1. Transmission cycles for yellow fever virus
* The jungle (sylatic) transmission cycle involves transmission of the virus between nonhuman primates and mosquito species found in the forest canopy. The virus is 
transmitted via mosquitoes from nonhuman primates to human when the humans encroach into the jungle during occupational or recreational activities. 
† The urban transmission cycle involves transmission of the virus between human and urban mosquitoes, primarily Ae. aegypti. Viremic humans traveling from one region 
to another can feed into and serve as a source of infection for mosquitoes in other transmission cycles (dotted line).
§ In Africa, an intermediate (savannah) cycle involves transmission of YFV from tree hole-breeding Aedes spp. to humans living or working in jungle border areas. In this 
cycle, the virus can be transmitted from nonhuman primate to humans or from human to human via these mosquitoes. 
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Epidemiology of Yellow Fever
Geographic Distribution and Spread
YF occurs in sub-Saharan Africa and tropical South America, 
where it is endemic and intermittently epidemic (Figure 2). 
Most YF disease in these areas is attributable to sylvatic or 
intermediate transmission cycles. However, urban transmis-
sion of YF does occur periodically in Africa and sporadically 
in South America (19–21).
In Africa, the majority of outbreaks have been reported from 
West Africa; fewer outbreaks have been reported from Central 
and East Africa (22). The reasons for this are unknown but 
might include higher densities of humans and Ae. aegypti in 
the west, genetic differences between YFV strains (genotypes) 
between the east and west, the presence of antibodies against 
other flaviviruses contributing to cross-protection, and mos-
quito species transmitting the disease in East Africa being 
less likely to bite humans (5,22,23). During West African 
outbreaks, up to 30% of the population is infected with YFV, 
and 3%–4% develop clinical disease (24,25). Since 2008, an 
increased number of YF cases have been reported from Central 
African countries (e.g., the Central African Republic, Congo, 
and Chad) (26,27; WHO, unpublished data, 2009). Many 
of these countries have reported YF cases infrequently in the 
past, and whether the recent reports of cases in these countries 
are attributable to improved surveillance or to increased dis-
ease activity either locally or via extension from neighboring 
endemic areas is unclear.
In South America, transmission of YFV occurs predomi-
nantly in sparsely populated forested areas rather than in urban 
areas. Most YF cases are reported from the Orinoco, Amazon, 
and Araguaia river basins and contiguous grasslands (28). 
Peru and Bolivia have the highest cumulative incidence of YF 
over the past 20 years (29). In Brazil, most cases are reported 
from the Amazon and western Brazil. However, starting in 
2007, cases have been identified in more southern and eastern 
provinces, including Sao Paulo, Rio Grande do Sul, and Goias 
states (30–32). During this same time, areas contiguous with 
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southern Brazil in northern Argentina and Paraguay also have 
had confirmed cases of YF, representing the first reemergence of 
the virus in these regions since the 1970s (31). In addition to 
the expansion of the endemic zone of the disease in recent years, 
Ae. aegypti also have reinfested many urban centers in South 
America, increasing the risk for urban outbreaks of YF in the 
Americas, as occurred in 2007 in Asunción, Paraguay (21).
Although urban outbreaks of YF occurred in North America 
and Europe until the early 1900s, autochthonous transmission 
has not been reported over the past several decades. Local YFV 
transmission never has been identified in Asia or Australia. 
However, these areas are at risk for importation, as many 
urban areas in these regions have Ae. aegypti and have a large 
susceptible human population (33). As a result, some countries 
in which the disease is not endemic (e.g., India and Australia) 
require proof of YF vaccination from travelers arriving from 
regions in which YFV is endemic (34).
Incidence and Burden of Disease
WHO estimates that 200,000 cases of YF and 30,000 deaths 
attributable to YF occur annually worldwide (6). However, only 
a limited percentage of these cases are identified because of 
underreporting (24,25). During 1988–2007, a total of 26,356 
YF cases were reported to WHO, including 23,056 (87%) 
cases from sub-Saharan Africa and 3,300 (13%) from South 
America (1,35–37). In Africa, the number of cases reported 
annually varies widely (range: 1–5,000), which suggests incon-
sistencies in surveillance and reporting. In South America, as 
many as 524 cases per year have been reported to WHO. The 
case-fatality ratio is highly variable but is approximately 20% 
in Africa and approximately 50% in South America (1). The 
higher case-fatality ratio in South America is believed to be 
the result of enhanced diagnostic testing of persons with fatal 
disease rather than an indication of a more virulent form of 
the disease (5).
Ecologic and Seasonal Patterns
The ecology of YFV is complex, and multiple factors con-
tribute to its transmission. In general, increased temperature, 
humidity, and rainfall lead to higher mosquito abundance and 
consequently an increase in viral circulation (38,39). In South 
America, YF incidence is highest during months of increased 
rainfall, humidity, and temperature (January–May) (40). In 
intermediate zones of West Africa, YFV activity increases dur-
ing the middle of the rainy season (around August) and peaks 
during the early dry season (October) (40,41). This period 
corresponds to the period of maximum longevity of mosquito 
vectors. Because Ae. aegypti breed in containers used for water 
storage, mosquito activity and reproduction patterns are less 
dependent on rainfall (41). As a result, when Ae. aegypti are 
involved in virus transmission, YF also can occur in the dry 
season.
FIGURE 2. Areas* at risk for yellow fever transmission — Africa and South America, 2009
Source: Brunette GW, Kozarsky PE, Magill AJ, Shlim DR, Whatley AD, eds. CDC health information for international travel 2010. Atlanta. GA: US Department of Health 
and Human Services, Public Health Service, CDC; 2009.
* As defined by the World Health Organization, countries/areas where yellow fever has been reported currently or in the past, plus areas where vectors and animal 
reservoirs currently exist.
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Age-Specific Patterns
The age-specific patterns of YF disease in Africa and South 
America differ and are affected by sex and occupation. In Africa, 
cases often occur in villages in the savannah region contiguous 
with the forest. Children are predominantly affected, as older 
persons in the community frequently have naturally acquired 
or vaccine-acquired immunity (24). In South America, YF 
disease occurs most frequently in unvaccinated young men 
who are exposed to mosquito vectors through their work in 
forested or jungle areas (42,43). Occupations involving lum-
bering and forest clearing for building or road construction 
have been linked to human infection (28). The age and sex 
distribution of YF cases in urban areas of South America differs 
from that observed in jungle areas, with a higher prevalence of 
infections occurring among children and women attributable 
to Ae. aegypti breeding around homes (21).
Clinical Manifestations and Diagnosis
Signs and Symptoms
In the majority of persons infected with YFV, infections are 
believed to be asymptomatic (24,25). Clinical disease varies 
from a mild, undifferentiated febrile illness to severe disease 
with jaundice and hemorrhagic manifestations. The incubation 
period is usually 3–6 days (1,2). In its mildest form, YF is a 
self-limited infection characterized by sudden onset of fever 
and headache without other symptoms (3). Other patients 
experience an abrupt onset of a high fever (up to 104°F [40°C]), 
chills, severe headache, generalized myalgias, lumbosacral pain, 
anorexia, nausea, vomiting, and dizziness (4,43). The patient 
appears acutely ill, and examination might demonstrate bra-
dycardia in relation to the elevated body temperature (Faget’s 
sign). The patient is usually viremic during this period, which 
lasts for approximately 3 days. Many patients have an unevent-
ful recovery, but in approximately 15% of infected persons, 
the illness recurs in more severe form within 48 hours follow-
ing the viremic period (44). Symptoms include fever, nausea, 
vomiting, epigastric pain, jaundice, renal insufficiency, and 
cardiovascular instability (4). Viremia generally is absent during 
this phase of symptom recrudescence. A bleeding diathesis can 
occur, with hematemesis, melena, metrorrhagia, hematuria, 
petechiae, ecchymoses, epistaxis, and oozing blood from the 
gingiva and needle-puncture sites. Physical findings include 
scleral and dermal icterus, hemorrhages, and epigastric tender-
ness without hepatic enlargement (44).
Clinical Laboratory Findings
Multiple laboratory abnormalities can be observed in patients 
with YF; these can vary depending on the severity and stage of 
illness. In the first week of the illness, leukopenia might occur; 
however, leukocytosis also can occur during the second week 
of the disease (3). Bleeding dyscrasias also can occur, together 
with elevated prothrombin and partial thromboplastin times, 
decreased platelet count, and presence of fibrin-split products 
(45,46). Hyperbilirubinemia might be present as early as the 
third day but usually peaks toward the end of the first week 
of illness. Elevations of serum transaminase levels occur in 
severe hepatorenal disease and might remain elevated for up 
to 2 months after onset (47).
Preliminary diagnosis is based on the patient’s clinical 
features, YF vaccination status, and travel history, includ-
ing destination, time of year, and activities. Mild YF cannot 
be distinguished clinically from a range of other infections. 
Cases of YF with jaundice must be differentiated from viral 
hepatitis, malaria, leptospirosis, Congo-Crimean hemorrhagic 
fever, Rift Valley fever, typhoid, Q fever, and typhus, as well as 
surgical, drug-induced, and toxic causes of jaundice (17). The 
other viral hemorrhagic fevers, which usually manifest with-
out jaundice, include dengue hemorrhagic fever, Lassa fever, 
Marburg and Ebola virus diseases, and Bolivian, Argentinean, 
and Venezuelan hemorrhagic fevers (48,49).
Laboratory Confirmation
Laboratory diagnosis generally is accomplished by testing 
serum to detect virus-specific immunoglobulin M (IgM) and 
immunoglobulin G (IgG) antibodies by serologic assays (50). 
Serologic cross-reactions occur with other flaviviruses (e.g., 
West Nile or dengue viruses), so positive results should be 
confirmed with a more specific test (e.g., plaque reduction neu-
tralization test) (49). Early in the illness (during the first 3–4 
days), YFV or YFV RNA often can be detected in the serum 
by virus isolation or nucleic acid amplification testing (e.g., 
reverse transcription-polymerase chain reaction [RT-PCR]). 
However, by the time overt symptoms are recognized, the virus 
or viral RNA usually is undetectable. Therefore, virus isolation 
and RT-PCR should not be used for excluding the diagnosis of 
YF. Immunohistochemical staining of formalin-fixed material 
can detect YFV antigen on histopathologic specimens (51). 
Health-care providers should contact their state or local health 
department and CDC (at telephone 1-970-221-6400) for 
assistance with diagnostic testing for YFV infections.
treatment and Management
Although multiple drugs have been evaluated or used 
empirically to treat YF disease, to date, none has demonstrated 
specific benefit (52). Management is supportive and based 
on symptoms and the organ systems involved. Patients with 
multisystem organ involvement likely will require critical-care 
support with possible mechanical ventilation or hemodialysis. 
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Rest, fluids, and nonsteroidal anti-inflammatory drugs or acet-
aminophen can relieve milder symptoms of fever and myalgias. 
Aspirin should be avoided because of the risk for hemorrhagic 
complications. Infected persons should be protected from 
further mosquito exposure (staying indoors and/or under a 
mosquito net) during the first few days of illness so they do 
not contribute to the transmission cycle.
outcome and Sequelae
The majority of persons with mild YF illness recover without 
long-term sequelae. For those with severe disease involving 
hepatorenal dysfunction, the length of illness is variable, and 
the case-fatality ratio is 20%–50% (1). Risk factors for death 
include hypotension, shock, renal failure, severe hemorrhagic 
disease, coma, and convulsions (44). For those who survive, 
convalescence often is prolonged, lasting several weeks. Rarely, 
death can occur at the end of convalescence or even weeks after 
complete recovery from the acute illness. These late deaths 
are thought to be attributable to myocardial damage and 
cardiac arrhythmia (53). Secondary bacterial infections (e.g., 
pneumonia) also can complicate recovery. Jaundice has been 
observed for up to 3 months after recovery from serologically 
documented YF (45).
Yellow Fever Among travelers
During 1970–2009, nine cases of YF were reported in 
unvaccinated travelers from the United States and Europe 
who traveled to West Africa (five cases) or South America (four 
cases) (54–63). Eight of these nine travelers died (19,40). Only 
one case of YF has been documented in a vaccinated traveler, 
a female aged 37 years from Spain who visited several West 
African countries during 1988 (56).
A traveler’s risk for acquiring YF is determined by multiple 
factors, including immunization status, use of personal protec-
tion measures against mosquito bites, location of travel, dura-
tion of exposure, occupational and recreational activities while 
traveling, and local rate of virus transmission at the time of 
travel. In both West Africa and South America, YFV transmis-
sion typically is seasonal and is associated with the mid-to-late 
rainy season ( ). However, YFV can be transmitted by Ae. 
aegypti even during the dry season in both rural and densely 
settled urban areas (41). Although the number of reported 
cases of human disease often is used to estimate the crude level 
of endemic transmission, cases might not be reported because 
of a low level of transmission, a high level of immunity in the 
local population (e.g., because of vaccination), or cases not 
being detected by local surveillance systems. Therefore, a lack 
of human disease cases in an area does not equate to absence 
of risk for transmission.
The risk for acquiring YF is difficult to predict because of 
variations in ecologic determinants of virus transmission. For 
a 2-week stay, the estimated risks for illness and death attribut-
able to YF for an unvaccinated traveler traveling to an area of 
West Africa where the disease is endemic are 50 and 10 cases 
per 100,000 population, respectively; for South America, 
the risks for illness and death are five cases and one case per 
100,000 population, respectively (40). These crude estimates 
for unvaccinated travelers are based on risk to indigenous 
populations, often during peak transmission season. Thus, 
these risk estimates might not reflect accurately the actual risk 
to travelers, who might have a different immunity profile, take 
precautions against getting bitten by mosquitoes, and have less 
outdoor exposure. The risk for acquiring YF in South America 
might be lower than that in Africa because the mosquitoes that 
transmit the virus between monkeys in the forest canopy do not 
come in contact with humans often, and local residents have 
a relatively high level of immunity secondary to widespread 
vaccine use.
Yellow Fever Vaccine
YF vaccine was first developed in the 1930s after success-
ful attenuation of the Asibi strain of YFV (64). Two vaccines 
were established: the 17D and the French neurotropic vac-
cines. The French neurotropic vaccine was manufactured 
until 1982, when production was stopped because of higher 
rates of neurologic adverse events reported following use of 
the vaccine (1).
Two 17D substrain vaccines are manufactured today: the 
17DD and 17D-204 YF vaccines. The YFV strains in these 
two vaccines share 99.9% sequence homology (65). The 17DD 
YF vaccine is manufactured in Brazil and is used in Brazil and 
many other South American countries. The 17D-204 vaccine 
is manufactured and used outside of Brazil, including in the 
United States. Studies comparing the various 17D YF vaccines 
produced by multiple manufacturers suggest that the reacto-
genicity or immune responses generated by these vaccines do 
not differ (66–70). Thus persons who receive YF vaccines in 
countries other than the United States should be considered 
protected against YF.
Vaccine Composition, Storage, 
and Handling
The 17D-204 strain vaccine, YF-VAX (manufactured by 
sanofi pasteur, Swiftwater, Pennsylvania), is a freeze-dried 
supernatant of centrifuged embryo homogenate, packaged in 
1-dose and 5-dose vials for domestic use. The vaccine should 
be stored at temperatures of 35ºF–46ºF (2ºC–8ºC) until it is 
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reconstituted by the addition of diluent (sterile, physiologic 
saline) supplied by the manufacturer. Multidose vials of recon-
stituted vaccine should be stored at 35ºF–46ºF (2ºC–8ºC) for 
up to 1 hour. Any unused vaccine that is not used within 1 
hour of reconstitution must be discarded (71).
Correlates of Protection
No human studies have been performed to determine the 
correlates of protection for YFV infection. However, dose-
response studies conducted in rhesus monkeys have established 
the minimal level of neutralizing antibodies needed to protect 
the monkeys against virulent YFV. Testing was conducted with 
constant amounts of serum and varying dilutions of virus to 
establish a log10 neutralization index (LNI). These studies 
demonstrated that LNI >0.7 was correlated strongly with 
protection (1,72). Although the amount of serum needed for 
LNI testing is suitable for animal studies or clinical trials, it 
precludes routine screening among humans (1). Therefore, 
a similar test, plaque reduction neutralization test (PRNT), 
which uses a constant amount of virus and varying dilutions 
of serum, is used most frequently in diagnostic tests to deter-
mine the absence or presence of neutralizing antibodies and 
the specific serum antibody titer.
Efficacy and Immunogenicity
No human efficacy studies have been performed with YF 
vaccine. However, several observations support YF vaccine 
being protective in humans, including 1) the reduction of 
laboratory-associated infections in vaccinated workers, 2) the 
observation following initial use of the vaccine in Brazil and 
other South American countries that YF occurred only in 
unvaccinated persons, and 3) the rapid disappearance of cases 
during YF vaccination campaigns initiated during epidemics. 
Unpublished reports comparing YF incidence among vacci-
nated and unvaccinated populations during a 1986 epidemic 
in Nigeria estimated vaccine effectiveness to be approximately 
85% (1). Worldwide, only five cases of YF have been reported 
in vaccine recipients since YF vaccine has been in use; whether 
any or all of them were vaccinated properly with appropriately 
handled YF vaccine is uncertain (1).
Following YF vaccine administration, primary vaccine recipi-
ents often develop a low-level viremia with the vaccine virus. 
The viremia usually occurs within 3–7 days and persists for 1–3 
days, abating as YFV IgM antibodies are developed (73,74). 
The level of viremia following vaccination is high enough to 
be transmitted through blood products. Transfusion-related 
transmission of YF vaccine virus has been documented in three 
persons who received blood products that were collected from 
persons vaccinated 4 days before their blood donation (75).
Studies have demonstrated that 80%–100% of vaccinated 
persons develop neutralizing antibodies by 10 days after 
vaccination (74,76,77). Most studies indicate that >99% of 
vaccinated persons developed YFV neutralizing antibodies by 
28 days after vaccination (1). Overall, the vaccine-induced 
antibodies are delayed in their formation and at lower titers 
compared with antibodies developed in response to wild-type 
YFV infection (1).
A study of two YF vaccines (YF-VAX and Arilvax) in 1,440 
healthy adults found different neutralizing antibody responses 
to the vaccine, depending on sex and race. For both vaccines, 
males and Caucasians were noted to have higher LNI levels 
when compared with females, blacks, and Hispanics (66). The 
age at which a person is vaccinated with YF vaccine does not 
appear to affect immunologic response to the vaccine (1).
IHRs allow countries to require proof of YF vaccination as a 
condition of entry for travelers arriving from certain countries 
to prevent importation and indigenous transmission of YFV. 
IHRs stipulate that the vaccination certificate for YF is valid 
beginning 10 days after administration of YF vaccine for pri-
mary vaccine recipients (78). This time period corresponds to 
the time at which the majority of vaccinees demonstrate immu-
nity. The YF vaccination certificate for international travel is 
valid for 10 years. This interval was based on published studies 
indicating that neutralizing antibodies were present in >90% 
of persons 16–19 years after vaccination (79). Later studies of 
U.S. military veterans from World War II tested 30–35 years 
after a single dose of YF vaccine demonstrated that >80% had 
neutralizing antibody; in certain subgroups, >95% still had 
neutralizing antibodies (80).
Healthy persons rarely fail to develop neutralizing antibod-
ies following YF vaccination. In controlled clinical trials, the 
primary failure rate is generally about 1% (66). Persons who 
fail to develop antibody after their first vaccination can develop 
antibody upon revaccination (81).
Three host factors have been associated with failure to 
respond immunologically to YF vaccine: pregnancy, human 
immunodeficiency virus (HIV) infection, and malnutrition. 
In one study, only 39% of pregnant women seroconverted 
after receiving the vaccine in their third trimester (82). This 
difference was attributed to the altered immune state associated 
with pregnancy and suggests the need to revaccinate at-risk 
women who were vaccinated during pregnancy. However, a 
more recent study indicated that 425 (98%) of 441 women 
who were vaccinated inadvertently with YF vaccine, primarily 
during their first trimester, developed YFV-specific neutral-
izing antibodies (83). Therefore, revaccination might not be 
necessary in women who received vaccine during pregnancy, 
but antibody titers should be checked to ensure an appropriate 
immune response in women still at risk for the disease.
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HIV infection has been associated with a reduced immu-
nologic response to a number of inactivated and live, attenu-
ated vaccines, including YF vaccine (84). Some case reports 
have suggested that vaccinating HIV-infected persons who 
are not immunosuppressed (CD4+ T-cell count [CD4 count] 
>500/mm3) results in seroconversion (85). However, a recent 
retrospective cohort study indicated that significantly fewer 
HIV-infected persons had YFV neutralizing antibodies at 1 
year after vaccination compared with vaccinated uninfected 
persons (83% and 97%, respectively; p=0.01) (86). The study 
measured YFV neutralizing antibodies in HIV-infected persons 
with median baseline CD4 count of 496 cells/mm3 (range: 
72–1,730 cells/mm3) and varying levels of HIV RNA detected 
in their blood (52% had HIV RNA levels ≥50 copies/mL). 
Among HIV-infected infants in one developing nation, only 
17% developed neutralizing antibodies within 10 months of 
YF vaccine compared with 74% of HIV-uninfected controls 
matched for age and nutritional status (87). The mechanisms 
for this observed difference in immune response among HIV-
infected persons are uncertain but appear to correlate with 
HIV RNA level and CD4 count. Further studies are required 
to assess the relevance of these findings.
Adverse Events
General Events
After YF vaccination, vaccinees have reported mild head-
aches, myalgia, low-grade fevers, or other minor symptoms for 
5–10 days (71). Localized pain, swelling, erythema, or warmth 
might occur at the injection site for up to a week following 
vaccination. In one large study of 1,440 vaccine recipients, 
the most common systemic side effects were headache (33% 
of subjects), myalgia (25%), malaise (19%), fever (15%), 
and chills (11%) (66). These side effects generally were mild, 
and only 1% of vaccinees curtailed their regular activities as 
a result. In the only placebo-controlled trial of 1,007 adults 
vaccinated with either YF vaccine (the 17-DD vaccine virus 
strain) or placebo, 3% of reported local reactions and 7% of 
systemic reactions were attributed to vaccine (88).
The Vaccine Adverse Event Reporting System (VAERS) 
is a passive surveillance system for adverse events following 
vaccination operated collaboratively by CDC and FDA. 
Adverse event reports can be submitted to VAERS from a 
variety of sources, including vaccine providers and recipients, 
medical practitioners, and manufacturers. The rate of any 
adverse events following YF vaccine as reported to VAERS 
is 43 adverse events per 100,000 doses distributed (89). The 
majority of reported adverse events are classified as nonserious 
(rate: 38 per 100,000 population) and include reports of fever, 
injection-site pain, injection-site erythema, pruritis, headache, 
urticaria, and rash. The majority of events occur a median of 
1 day after vaccination; roughly 60% occur within the first 2 
days after vaccination.
During 2000–2006, a rate of 4.7 serious adverse events per 
100,000 doses distributed was derived from VAERS data. 
Reporting rates were highest among persons aged ≥60 years 
(8.3 per 100,000 doses). Three well-characterized serious 
adverse events occur following YF vaccine administration: 1) 
immediate hypersensitivity or anaphylactic reactions, 2) YF 
vaccine-associated neurologic disease (YEL-AND), and 3) YF 
vaccine-associated viscerotropic disease (YEL-AVD).
In 2002, CDC formed the Yellow Fever Vaccine Safety 
(YFVS) Working Group, consisting of vaccine safety experts 
from CDC and partner organizations. The YFVS Working 
Group systematically reviewed VAERS reports for YF vaccine 
and devised a surveillance case definition for YEL-AND and 
YEL-AVD (Boxes 1 and 2) to help classify cases and determine 
rates of these adverse events.
Hypersensitivity and Anaphylactic Reactions
Multiple components of YF vaccine have been cited as pos-
sible allergens, including eggs, chicken proteins, gelatin, or 
latex (found in vial stopper) (71). Immediate hypersensitivity 
reactions or anaphylaxis, characterized by urticaria and respira-
tory symptoms (e.g., dyspnea, bronchospasm, or pharyngeal 
edema) are uncommon and occur principally among persons 
with histories of allergies to egg or other substances (90). 
However, anaphylaxis has been reported to occur in persons 
with no history of reactions to the vaccine’s components. Rates 
of anaphylaxis from VAERS data vary (range: 0.8–1.8 events 
per 100,000 doses distributed) (89,90).
YEL-AnD
YEL-AND is a serious but rarely fatal adverse event. YEL-
AND manifests as several distinct clinical syndromes, includ-
ing meningoencephalitis (neurotropic disease), Guillain-Barré 
syndrome (GBS), acute disseminated encephalomyelitis 
(ADEM), and bulbar palsy (91,92). Meningoencephalitis 
occurs as a result of direct YF vaccine viral invasion of the 
central nervous system (CNS) with infection of the meninges 
and/or the brain. The other neurologic syndromes (e.g., GBS 
and ADEM) represent autoimmune manifestations in which 
antibodies and/or T-cells produced in response to the vac-
cine cross-react with neuronal epitopes and lead to central or 
peripheral nerve damage.
Through the attenuation process, YF vaccine virus strains 
were determined to develop neurovirulence (93,94). Early in 
the vaccine’s history, multiple cases of encephalitis associated 
with vaccine administration were noted and determined to 
be attributable to too few or too many passages of the virus 
Vol. 59 / RR-7 Recommendations and Reports 9
BOX 1. CDC’s Yellow Fever Vaccine Safety (YFVS) Working Group case definition* for yellow fever vaccine-associated neurologic disease 
(YEL-AND)
Case ascertainment
Level 1: neurologic disease 
•	 One	or	more	of	the	following	signs	and	symptoms:
– fever (≥100.5°F [>38.1°C] for >24 hours) and headache 
(>24 hours) 
– focal neurologic dysfunction (including but not limited to 
ataxia, aphasia, and paresis)
– mental status change (confusion, lethargy, or personality 
change lasting >24 hours)
– new onset seizure or recurrence of previously controlled 
seizures
– cerebrospinal fluid (CSF) pleocytosis (>5 WBC/mm3)
– elevated CSF protein (>1.5 times the normal limit)
Level 2: neurotropic disease
•	 Level	1	neurologic	disease,	and
•	 one	or	more	of	the	following:
– neuroimaging consistent with inflammation, (with or with-
out demyelination)
– electroencephalogram finding consistent with 
encephalopathy
Level 2: autoimmune disease with central nervous system 
involvement
•	 Level	1	neurologic	disease,	and
•	 neuroimaging	consistent	with	multifocal	or	disseminated	
areas of demyelination
Level 2: autoimmune disease with peripheral nervous system 
involvement
•	 Level	1	neurologic	disease,† and
•	 two	or	more	of	the	following	signs	and	symptoms:
– limb weakness with decreased or absent tendon reflexes
– cranial nerve abnormalities 
– autonomic dysfunction (including but not limited to 
postural hypotension, arrhythmias, abnormal sweating, and 
gastric motility abnormalities)
– numbness or paresthesias in the extremities
– electromyography finding consistent with Guillain-Barré 
syndrome
Case definitions
Yellow fever vaccine-associated neurotropic disease
Suspect neurotropic disease
•	 Onset	of	symptoms	and	signs	occurs	within	1–30	days	of	
vaccination with yellow fever vaccine, either given alone or in 
combination with other vaccinations;
•	 level	2	neurotropic	disease;	and
•	 no	evidence	of	other	diagnoses
Probable neurotropic disease
•	 Suspect	YEL-AND,	and
•	 one	or	more	of	the	following:
– vaccine-type yellow fever viral isolation from blood (>7 
days postvaccination)
– yellow fever 17D§ virus concentration in serum on any day 
exceeds 3 log10 pfu/mL 
Definite neurotropic disease
•	 Suspect	YEL-AND,	and
•	 one	or	more	of	the	following:
– YF-specific CSF IgM 
– yellow fever 17D§ virus isolation from CSF 
– amplification of vaccine type virus§ from CSF 
Yellow fever vaccine-associated autoimmune disease with 
central nervous system involvement (YEL-AAD-CNS)
Suspect YEL-AAD-CNS
•	 Onset	of	symptoms	and	signs	occurs	within	1–30	days	of	
vaccination with yellow fever vaccine, either given alone or in 
combination with other vaccinations;
•	 level	2	autoimmune	disease	with	central	nervous	system	
involvement; and
•	 no	evidence	of	other	diagnoses
Probable YEL-AAD-CNS
•	 Suspect	autoimmune	disease	with	central	nervous	system	
involvement, and
•	 YEL	administered	alone
Yellow fever vaccine-associated autoimmune disease with 
peripheral nervous system involvement (YEL-AAD-PNS)
Suspect YEL-AAD-PNS
•	 Onset	of	symptoms	and	signs	occurs	within	1–30	days	of	
vaccination with yellow fever vaccine, either given alone or in 
combination with other vaccinations; 
•	 level	2	autoimmune	disease	with	PNS	involvement;	and
•	 no	evidence	of	other	diagnoses
Probable YEL-AAD-PNS
•	 Suspect	autoimmune	disease	with	PNS	involvement,	and
•	 YEL	administered	alone
* A modified version of the case definitions has been published (Monath T, Cetron MS, Teuwen DE. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit 
PA, eds. Vaccines. 5th ed. Philadelphia, PA: Saunders Elsevier; 2008:959–1055). These case definitions 1) define cases of neurologic disease, 2) define cases 
with autoimmune involvement in the central nervous system or peripheral nervous system, and 3) describe causal linkage to yellow fever vaccine. Another 
laboratory-confirmed diagnosis that explains the clinical picture fully might be sufficient to exclude yellow fever vaccine-associated disease. Given the challenges 
in procuring sufficient evidence to make a definitive diagnosis, it might be necessary to combine suspect, probable, and definite cases for risk factor analysis 
and case counting.
† Does not require presence of altered mental status or seizures.
§ Confirmed as 17D virus by monoclonal antibody analysis or nucleotide sequencing when a possibility of wild-type YF infection exists, inclusive of all 
17D-derived vaccines.
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during the attenuation process. This observation led to the 
establishment of a vaccine seed lot system in 1945 that clearly 
defined the number of passages allowed for certain strains of 
the vaccine (95). However, even after the implementation of 
the seed lot system, additional cases of encephalitis associated 
with YF vaccine continued to be reported. Studies conducted 
during the early 1950s identified four cases of encephalitis out 
of 1,000 children aged <6 months vaccinated with YF vaccine 
(96). An additional 10 cases of encephalitis associated with YF 
vaccine administered to infants aged <4 months were reported 
worldwide during the 1950s (1). Consequently, recommenda-
tions were made in the 1960s restricting the use of YF vaccine 
to infants aged ≥6 months (97). Subsequently, the number of 
cases of encephalitis reported in infants diminished.
A total of 29 cases of YEL-AND (nine of meningoencepha-
litis, eight of GBS, three of ADEM, one of bulbar palsy, and 
eight cases with insufficient data to classify) that occurred dur-
ing 1990–2006 were reviewed retrospectively or prospectively 
by the YFVS Working Group (91,92,98,99). The 29 cases 
had a varied time from vaccination to symptom onset (range: 
Case ascertainment
Level 1: viscerotropic disease (for surveillance)
•	 Fever	(≥100.5°F	[(>38.1°C]	for	>24	hours),	and
•	 one	or	more	of	the	following	signs	and	symptoms:
– nausea
– vomiting
– malaise (duration >72 hours)
– myalgia (duration >24 hours)
– arthralgia (duration >24 hours)
– dyspnea
Level 2: viscerotropic disease 
•	 Level	1	viscerotropic	disease;	and
•	 one	or	more	of	the	following	signs:
– jaundice (total bilirubin elevated 1.5 times normal)
– liver dysfunction (elevation of AST and ALT three times 
above normal)
– renal impairment (decrease in glomerular filtration rate, as 
measured by an elevation over 1.5 times in BUN or creati-
nine and no history of renal disease)
– tachycardia (heart rate >100 beats per minute) or bradycar-
dia (<50 beats per minute)
– rhabdomyolysis (>5 times normal CPK)
– respiratory distress (shortness of breath, ventilation 
or oxygenation impairment)
– thrombocytopenia (platelets <100,000/µL)
– hypotension (systolic blood ≤90 mm Hg for adults 
or less than fifth percentile by age for children aged <16 
years; orthostatic drop in diastolic blood pressure ≥15 mm 
Hg from lying to sitting, orthostatic syncope, or orthostatic 
dizziness)
– myocarditis (compatible abnormalities including 
electrocardiogram, echocardiogram, or cardiac enzyme 
changes, or inflammation by tissue biopsy)
– disseminated intravascular coagulation (elevation of pro-
thrombin time or activated partial thromboplastin time 
with fibrin split products)
– hemorrhage
Case definitions
Yellow fever vaccine-associated viscerotropic disease (YEL-
AVD)
Suspect YEL-AVD
•	 Onset	of	symptoms	and	signs	occurs	within	1–10	days	of	
vaccination with yellow fever vaccine, either given alone or in 
combination with other vaccinations;
•	 level	2	viscerotropic	disease,	with	evidence	of	liver	
dysfunction; and
•	 no	evidence	of	other	diagnoses
Probable YEL-AVD 
•	 Suspect	YEL-AVD,	and
•	 one	or	more	of	the	following:
– histopathology consistent with yellow fever (e.g., 
liver midzonal necrosis, Councilman bodies) 
– yellow fever 17D† isolation from blood (>7 days 
postvaccination)
– yellow fever 17D† virus concentration in serum on any day 
exceeds 3 log10 pfu/mL 
Definite YEL-AVD
•	 Suspect	YEL-AVD,	and
•	 one	or	more	of	the	following:
– YF-specific antigen in tissue demonstrated by 
immunohistochemistry (IHC) 
– yellow fever 17D† virus isolation from tissue 
– amplification of yellow fever 17D† virus from tissue 
BOX 2. CDC’s Yellow Fever Vaccine Safety (YFVS) Working Group case definition* for yellow fever vaccine-associated viscerotropic disease 
(YEL-AVD)
* A modified version of these case definitions has been published (Monath T, Cetron MS, Teuwen DE. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, 
Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: Saunders Elsevier; 2008:959–1055.) These case definitions define cases of viscerotropic disease and levels 
of certainty that might be causally linked to yellow fever vaccine. Absence of inclusion criteria does not exclude diagnosis of vaccine-associated viscerotropic 
disease (YEL-AVD); however, another laboratory-confirmed diagnosis that explains the clinical picture fully might be sufficient to exclude YEL-AVD. Given 
the challenges in procuring sufficient evidence to make a definitive diagnosis of YEL-AVD, it may be necessary to combine suspect, probable, and definite 
cases for risk factor analysis and case counting.
† Confirmed as 17D virus by monoclonal antibody analysis or nucleotide sequencing when a possibility of wild-type YF infection exists, inclusive of all 
17D-derived vaccines.
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3–28 days). For the 25 cases with data available on age, there 
again was a wide variation in age range (range: 6–78 years). All 
cases were reported to occur in first-time vaccine recipients. 
One death was reported in a male aged 53 years who had 
unrecognized asymptomatic human immunodeficiency virus 
(HIV) infection and CD4 count <200/mm3 (98). The patient 
developed fever and malaise 3 days after his vaccination and 
became encephalopathic at 5 days postvaccination. He died 
at 9 days following vaccination.
Data regarding the specific age and illness onset for the dif-
ferent neurologic presentations can be derived from VAERS 
reports (91). Of six reported encephalitis cases, the median age 
was 54 years (range: 16–78 years), and median time to onset 
after vaccination was 14 days (range: 5–24 days). For the six 
GBS cases, the median age was 53 years (range: 17–68 years), 
and median time to onset after vaccination was 13 days (range: 
7–27 days). Finally, for the three ADEM cases, the median age 
was 19 years (range: 18–61 years), and median time to onset 
after vaccination was 15 days (range: 7–20 days).
A recently published report has included the first report of 
a case of longitudinal myelitis in a male aged 56 years who 
received no other vaccines (100). YFV IgM antibodies were 
detected in his cerebrospinal fluid (CSF) and serologic test-
ing for other regional flaviviruses was negative. However, the 
time to symptom onset was 45 days after vaccination, which 
is longer than that reported for all other YEL-AND cases. A 
second recently published report concerned a male aged 23 
years who presented originally with meningoencephalitis but 
was later determined to have ADEM (101). The diagnosis of 
ADEM was determined by magnetic resonance imaging of 
the brain.
The diagnostic testing for YEL-AND is specific to the clini-
cal presentation. For cases with meningitis or encephalitis, the 
detection of the YF vaccine virus in CSF either by culture 
or nucleic acid amplification is diagnostic. The detection of 
YFV IgM and specific neutralizing antibodies in the CSF also 
supports the diagnosis. YFV IgM antibodies are not believed 
to cross the blood-brain barrier normally, so their production 
in CSF is considered indicative of local CNS infection. For 
autoimmune mediated events, no specific YF testing is avail-
able. The diagnosis of these conditions should be made using 
appropriate studies (e.g., neuroimaging, electroencephalog-
raphy, electromyelography, and nerve conduction studies). 
Because no confirmatory YFV-specific laboratory test exists for 
the autoimmune syndromes of ADEM and GBS, the YFVS 
Working Group case definition only specifies “suspect” and 
“probable” levels of causality. If no evidence of another diag-
nosis exists, a case is classified further depending on whether 
YF vaccine was the only vaccine administered. Diagnostic 
testing for suspected YEL-AND cases is available from CDC 
at http://www.cdc.gov/ncidod/dvbid/yellowfever/vaccine/
special-testing.htm.
Treatment for YEL-AND also depends on the particular 
clinical syndrome. Treatment for meningoencephalitis is sup-
portive, and manifestations such as seizures or autonomic 
dysfunction should be managed according to acceptable medi-
cal standards for each disorder. For autoimmune neurologic 
manifestations associated with YF vaccine, treatment often 
includes intravenous immune globulin (IVIG) or plasmaphere-
sis for GBS, and corticosteroids, IVIG, or plasmapheresis for 
ADEM (102,103).
YEL-AND rarely is fatal. In addition to the case described 
previously of fatal encephalitis in a person with HIV, four 
other deaths have been reported attributable to YEL-AND 
(1,104). One fatal case of encephalitis occurred in a girl aged 
3 years who was vaccinated in 1965 (104). Molecular studies 
of the YF vaccine virus isolated from the brain of this patient 
demonstrated that the virus had mutated and become more 
neurovirulent as documented in monkey studies (105). This is 
the only case in which a mutation of the vaccine virus has been 
linked to an adverse outcome in a recipient. Three other fatal 
YEL-AND cases were reported unofficially from a hospital-
based surveillance system for postvaccine encephalitis in Kenya 
after a mass vaccination campaign in 1993 (1).
The incidence rate of YF vaccine-associated encephalitis in 
very young infants has been estimated on the basis of reports 
from the time period before institution of the age restriction 
for vaccination to be 50–400 cases per 100,000 population 
(96,106). From VAERS data, the reporting rate for YEL-AND 
is 0.4–0.8 cases per 100,000 doses distributed (89,107). The 
reporting rate was higher for persons aged ≥60 years, with a 
rate of 1.6 cases per 100,000 doses distributed in persons aged 
60–69 years and 1.1–2.3 cases per 100,000 doses distributed 
for persons aged ≥70 years. These estimates most likely are low 
given underreporting. In countries in which YF is endemic, a 
national vaccine adverse event surveillance system might not 
exist or, if one does exist, be consistent and sensitive enough to 
detect the majority of YEL-AND cases that do occur. However, 
an unofficial report from a hospital-based surveillance system 
for postvaccine encephalitis in Kenya after a mass vaccination 
campaign estimated the incidence of YEL-AND to be 0.6 cases 
per 100,000 doses (1).
YEL-AVD
In 2001, a previously unrecognized serious adverse reaction 
among recipients of YF vaccine was first described (48,108–
113). This syndrome initially was termed febrile multiple organ 
system failure; the name subsequently was changed to YEL-
AVD. YEL-AVD mimics naturally acquired YF disease, with 
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the vaccine virus proliferating and disseminating throughout 
the host’s tissues.
As of February 2010, a total of 57 cases of YEL-AVD have 
been reported to CDC from 14 countries (Australia, Belgium, 
Brazil, China, Colombia, Ecuador, France, Germany, Japan, 
Peru, Spain, Switzerland, the United Kingdom, and the United 
States). The cases have occurred in association with the different 
substrains of YF vaccine produced by several manufacturers. 
On the basis of an analysis of cases for which information is 
available, YEL-AVD has occurred only following a recipient’s 
first YF vaccination; no cases of YEL-AVD occurring in persons 
receiving booster doses of the vaccine have been reported. Of 
the 53 persons with YEL-AVD cases whose sex is known, 32 
(60%) were male. The overall median age was 50 years (range: 
3–81 years) but differed by sex, with a median age of 62 years 
(range: 4–81 years) in males and 24 years (range: 3–79 years) 
in females. The median time from vaccination until symptom 
onset was 3 days (range: 1–8 days). Of 57 patients, 37 (65%) 
died, with a higher case-fatality ratio in females (19 [90%]) 
than males (16 [50%]) (sex was unknown in two fatal cases). 
The median time from YF vaccination until death was 10 
days (range: 7–30 days). Whether age and case-fatality ratio 
differences between sexes reflect sex-specific host factors or are 
a function of surveillance or reporting bias is unclear.
Patients with YEL-AVD typically develop fever and other 
nonspecific signs and symptoms (including headache, malaise, 
myalgias, nausea, vomiting, or diarrhea) within 1 week of 
vaccination. As the illness progresses, jaundice and laboratory 
abnormalities (e.g., thrombocytopenia, elevations of hepatic 
transaminases, total bilirubin, and creatinine) might occur. 
Leukopenia or leukocytosis might be present, depending on 
the stage and severity of the illness. Persons with severe cases 
can develop hypotension, hemorrhage, renal failure requiring 
hemodialysis, and respiratory failure requiring mechanical ven-
tilation. Less frequent complications include rhabdomyolysis 
and disseminated intravascular coagulation. No specific therapy 
exists for YEL-AVD, and, assuming other diseases have been 
excluded, treatment is supportive.
YF vaccine-specific laboratory testing can assist in making the 
diagnosis. Documentation of high levels of YF vaccine virus in 
the serum of patients within the first 7 days of vaccination or 
prolonged presence of replicating YF vaccine virus in blood >7 
days postvaccination is consistent with YEL-AVD (probable 
case). In fatal cases, when an autopsy has been performed, 
immunohistochemistry can be performed on fixed tissues 
to detect YFV antigen, and RT-PCR can be performed on 
RNA extracted from frozen tissues to verify the presence of 
YF vaccine virus versus wild-type YFV. Liver tissue can have 
characteristic histopathologic findings (e.g., midzonal necrosis, 
microvesicular fatty changes, and Councilman bodies) (114). 
Diagnostic testing for suspect YEL-AVD cases is available 
from CDC at http://www.cdc.gov/ncidod/dvbid/yellowfever/
vaccine/special-testing.htm.
Several risk estimates for YEL-AVD have been published. 
On the basis of VAERS data, the reporting rate of YEL-AVD is 
0.3–0.4 cases per 100,000 doses distributed (89,107). Similar 
to YEL-AND, reporting rates also are highest among persons 
aged ≥60 years, with rates of 1.0–1.1 cases per 100,000 doses 
distributed in persons aged 60–69 years and 2.3–3.2 cases 
per 100,000 doses distributed for persons aged ≥70 years. 
An analysis of YEL-AVD cases that occurred in Europe dur-
ing 1996–2003 yielded an overall incidence of 0.3 cases per 
100,000 doses distributed (92). A Brazilian analysis based on 
four fatal cases of YEL-AVD derived risk estimates of fatal 
YEL-AVD ranging from <0.01 to 0.21 per 100,000 doses 
administered (115). However, more recent risk estimates from 
Brazil have identified overall YEL-AVD rates similar to those 
from the United States and Europe (CDC, unpublished data, 
2010).
Almost all cases of YEL-AVD have occurred in persons 
who received different lots of vaccine. However, at least one 
known cluster has been reported involving five cases of YEL-
AVD associated with the same lot of YF vaccine (116). This 
cluster occurred in 2007 after a vaccination campaign in 
an area of Peru in which the disease was not endemic. Four 
patients died of confirmed YEL-AVD. The overall incidence 
of YEL-AVD in this campaign was 7.9 cases per 100,000 
doses distributed, compared with a lot-specific incidence of 
11.7 cases per 100,000 doses distributed for the implicated 
lot. A thorough investigation detected no abnormalities of the 
implicated vaccine lot and no common risk factors among the 
five case patients. The incidence of YEL-AVD associated with 
this campaign in Peru is substantially higher than previous risk 
estimates from other countries and remains unexplained.
To date, two specific risk factors for YEL-AVD have been 
identified: older age and a history of thymus disease or thymec-
tomy. The two analyses of VAERS reports of YEL-AVD in the 
United States yielded reporting rates of YEL-AVD for persons 
aged ≥60 years of 1.4–1.8 cases per 100,000 doses distributed 
(89,107). This age-specific rate is several-fold higher than the 
overall reported rate of 0.3–0.4 cases per 100,000 doses dis-
tributed. Four (17%) of the first 23 patients with YEL-AVD 
identified had a history of thymectomy for either a benign or 
malignant thymoma (117). The details of these cases suggest 
that a history of thymus disease is a risk factor for YEL-AVD. 
In 2003, the package insert for YF vaccine available in the 
United States was updated to include a history of thymus 
disorder as a contraindication to vaccine administration (71). 
No additional cases of YEL-AVD identified since 2004 have 
involved a history of thymus disease.
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A number of cases of YEL-AVD have involved a history of 
autoimmune disease or diseases with potential autoimmune 
etiology. These include three patients with systemic lupus 
erythematosis, two with Addison’s disease, one with Crohn’s 
disease in remission, one with a history of polymyalgia rheu-
matica and hypothyroidism, one with ulcerative colitis, and 
one with myasthenia gravis (108,116,117; CDC, unpublished 
data, 2010). These cases suggest that autoimmune disease 
might be a risk factor for YEL-AVD. However, four patients 
with underlying autoimmune disease were aged >60 years, two 
of whom had a history of thymectomy for a thymoma; both of 
these factors are associated with increased risk for YEL-AVD. 
Therefore, more information is needed regarding the number 
of patients with underlying autoimmune disease who are vac-
cinated safely to better address the potential risk for YEL-AVD 
in persons with autoimmune disease.
Although studies on certain cases of YEL-AVD have identi-
fied potential genetic risk factors (118), no common genetic 
abnormality has been demonstrated. No conclusive evidence 
has been reported that demonstrates that YEL-AVD has been 
caused by a reversion to increased virulence in the vaccine 
(114,119).
Vaccination of Women During 
Pregnancy and Breastfeeding
No data are available on the YF disease risk for pregnant or 
breastfeeding women and their fetuses or infants. However, 
on the basis of surveillance and outbreak data, pregnant and 
breastfeeding women do not appear to be at risk for more 
severe YF disease.
The use of YF vaccine during pregnancy has not been 
studied in a large prospective trial (FDA Pregnancy Category 
C). Limited data are available from a number of studies in 
which pregnant women either were vaccinated inadvertently 
or administered the vaccine in outbreak settings. Two studies 
involving 81 infants whose mothers had received YF vaccine 
identified YFV IgM antibodies in the cord blood of one infant 
shortly after birth (82,120). These findings suggest that infec-
tion of the fetus with YF vaccine can occur, albeit at a low inci-
dence (i.e., one of 81). A study of 304 infants born to women 
who were vaccinated with YF vaccine early in their pregnancies 
found no increased risk for major malformations (121). An 
increased risk was identified for minor malformations (e.g., 
pigmented nevi), but the finding could have resulted from 
assessment bias. One study of 39 pregnant women who were 
vaccinated with YF vaccine identified a higher rate of spontane-
ous abortions in pregnant women receiving the vaccine, with 
a relative risk of 2.3, but the difference was not statistically 
significant (95% confidence interval = 0.7–8.0; p=0.2) (122). 
A more recent study of 441 women inadvertently vaccinated 
early in their pregnancy did not find an increased risk for fetal 
death (7.4/1,000 in vaccinated women versus 18.5/1,000 
unvaccinated women in the general population) (83).
The proportion of women vaccinated during pregnancy who 
develop YFV antibodies is variable and might be related to the 
trimester in which they received vaccine. Of 101 pregnant 
women receiving YF vaccine predominantly in their third 
trimester, 39% had evidence of seroconversion to YFV (82). 
Of 433 women vaccinated predominantly in the first trimester, 
425 (98%) developed YFV-specific neutralizing antibodies 
(83). Because pregnancy might affect immunologic function, 
serologic testing to document an immune response to the vac-
cine should be considered.
No evidence exists that breastfeeding mothers have an altered 
response to YF vaccine. Very limited safety data are available on 
the use of YF vaccine in breastfeeding women and their infants. 
One probable and one confirmed case of YEL-AND have been 
reported in infants whose mothers were vaccinated with YF 
vaccine (PHAC, unpublished data, 2008; 123). Both infants 
were breastfed exclusively, were aged <1 month at the time of 
the exposure, and had not received the vaccine themselves. YF 
vaccine virus was recovered from the CSF of the confirmed 
case patient, and YFV-specific IgM antibodies were detected 
in the probable case-patient’s CSF. Testing was not performed 
on the breast milk in either case to confirm the presence of 
vaccine virus. RNA from West Nile virus, a related flavivirus, 
has been identified in breast milk, which suggests that this is 
a plausible mode of transmission (124,125). Further research 
is needed to document the risk for potential vaccine exposure 
through breastfeeding.
Summary of Rationale 
for YF Vaccine Recommendations
YF is a vectorborne disease resulting from the transmission 
of YFV to a human from the bite of an infected mosquito. It 
is endemic to sub-Saharan Africa and tropical South America. 
Infection in humans is capable of producing hemorrhagic 
fever and is fatal in 20%–50% of persons with severe disease. 
Because no treatment exists for YF disease, prevention is critical 
to lower disease risk and mortality.
The risk for acquiring YF for travelers is determined by mul-
tiple factors, including vaccination status, location of travel, 
season, duration of exposure, occupational and recreational 
activities while traveling, and local rate of virus transmission 
at the time of travel. Although only 10 cases of imported YF in 
travelers from Europe (seven cases) or the United States (three 
cases) have been reported since 1970, the low number of cases 
14 MMWR July 30, 2010
is likely, at least in part, to be a result of the routine use of the 
vaccine. In attempts to minimize the potential importation and 
spread of the disease into new areas, many countries enforce 
the IHR and have vaccine requirements for entry.
Decisions regarding the use of YF vaccine for travelers 
must take into account the overall risk for travel-associated 
YFV disease, the high mortality when it does occur, vaccine 
requirements per IHR, contraindications or precautions for 
vaccination, and risk for serious adverse events following YF 
vaccine administration.
Recommendations for the Use of 
YF Vaccine in Laboratory Workers
YF vaccine is recommended for laboratory personnel who 
might be exposed to virulent YFV or to concentrated prepara-
tions of YF vaccine virus strains by direct or indirect contact 
or by aerosols.
Recommendations for Prevention 
of YF Among travelers
All travelers to countries in which YF is endemic should be 
advised of the risks for the disease and available methods to pre-
vent it, including personal protective measures and vaccine.
Personal Protective Measures
All travelers should take precautions to avoid mosquito bites 
to reduce the risk for YF and other vector-borne infectious 
diseases. These precautions include using insect repellent, 
wearing permethrin-impregnated clothing, and staying in 
accommodations with screened or air-conditioned rooms. 
Additional information on protection against mosquitoes and 
other arthropods is available at http://wwwnc.cdc.gov/travel/
yellowbook/2010/chapter-2/protection-against-mosquitoes-
ticks-insects-arthropods.aspx.
Recommendations for the Use 
of YF Vaccine in travlers
YF vaccine is recommended for persons aged ≥9 months who 
are traveling to or living in areas at risk for YFV transmission 
in South America and Africa. Countries with risk for YFV 
transmission have been listed (Table 1). For many of these 
countries, only a portion of the country is at risk for YFV 
transmission (Figure 2). Given that changes in the designation 
of endemic regions can occur, travelers and health-care provid-
ers should obtain updated information from CDC, available 
at http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/
yellow-fever.aspx.
YF vaccine may be required for entry into certain countries. 
A list of country-specific requirements is available at http://
wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/yellow-
fever-vaccine-requirements-and-recommendations.aspx. 
Requirements are mandatory and are intended primarily to 
prevent importation into and transmission of YFV within a 
given country. However, IHRs stipulate that a medical provider 
may issue a waiver of YF vaccination to a traveler to fulfill 
these requirements if the provider judges that YF vaccination 
is medically contraindicated.
Because of the risk for serious adverse events that can occur 
following YF vaccine administration, health-care providers 
should vaccinate only persons who are at risk for exposure to 
YF virus or require proof of vaccination for country entry. To 
minimize further the risk for serious adverse events, health-care 
providers should observe the contraindications carefully and 
TABLE 1. Countries with risk for yellow fever virus (YFV) transmission* 
Africa Central and South America
Angola
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic
Chad†
Congo, Republic of the
Côte d’Ivoire
Democratic Republic of the Congo
Equatorial Guinea
Ethiopia
Gabon
The Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Liberia
Mali†
Mauritania†
Niger†
Nigeria
Rwanda
Sierra Leone
São Tomé and Principe
Senegal
Somalia
Sudan†
Tanzania
Togo
Uganda
Argentina†
Bolivia†
Brazil†
Colombia
Ecuador†
French Guiana
Guyana
Panama†
Paraguay
Peru†
Suriname
Trinidad and Tobago†
Venezuela†
* As defined by the World Health Organization, countries/areas where yellow fever has been reported currently or in the past, plus areas where vectors and animal 
reservoirs currently exist.
† These countries are not holoendemic (i.e., only a portion of the country has risk for YFV transmission). Information about which areas are endemic is available at 
http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/yellow-fever.aspx.
Vol. 59 / RR-7 Recommendations and Reports 15
consider the precautions to vaccination before administration 
of YF vaccine and provide a medical waiver when needed 
(Table 2).
Requirements for Vaccination 
Before International travel
Certain countries require evidence of vaccination from all 
entering travelers, which includes direct travel from the United 
States (34). Travelers who arrive in a country with a YF vac-
cination entry requirement without proof of vaccination may 
be quarantined for up to 6 days.
Country-entry requirements for proof of YF vaccination 
under IHRs are different from ACIP or CDC recommenda-
tions. Requirements are mandatory and are intended primarily 
to prevent importation into and transmission of YFV within 
a given country. CDC’s recommendations are public health 
advice provided to travelers on the basis of the best available 
epidemiologic data to prevent YFV infection among travelers 
visiting countries with a risk for YFV transmission.
For purposes of international travel, YF vaccines must be 
administered at an approved YF vaccination center. In the 
United States, state and territorial health departments have 
the authority to designate nonfederal vaccination centers 
and to issue YF vaccination stamps to those centers. A list of 
designated vaccine centers is available from CDC at http://
wwwnc.cdc.gov/travel or can be obtained from state or local 
health departments.
As proof of receipt of YF vaccine, all vaccinees should 
possess a completed International Certificate of Vaccination or 
Prophylaxis (ICVP), validated with the provider’s signature and 
official YF vaccination center stamp (Figure 3). An ICVP must 
be complete in every detail; if it is incomplete or inaccurate, it 
is not valid. Failure to secure validations can cause a traveler 
to be quarantined, denied entry, or possibly revaccinated at 
the point of entry to a country. Some countries do not require 
an ICVP for infants younger than a certain age (e.g. aged <6 
months, <9 months, or <1 year, depending on the country). 
Information on age requirements for vaccination by individual 
countries is available at http://wwwnc.cdc.gov/travel.
The certificate of vaccination is valid beginning 10 days after 
the date of vaccination and extending for a period of 10 years. 
When a booster dose of the vaccine is administered within this 
10-year period, the certificate is considered valid from the day 
of the most recent vaccination.
IHRs stipulate that a medical provider may issue a waiver 
of YF vaccination to a traveler if the provider judges that YF 
vaccination is medically contraindicated (see Contraindications 
and Precautions). In this case, the physician should fill out and 
sign the “Medical Contraindications to Vaccination” section 
of the ICVP (Figure 4), provide a signed and dated letter on 
letterhead stationary clearly stating the contraindication, and 
bearing that center’s official YF vaccination stamp. The pro-
vider should inform the traveler of any increased risk for YF 
infection associated with nonvaccination and how to minimize 
this risk. Reasons other than medical contraindications are not 
acceptable for exemption from vaccination. The traveler also 
should be advised of the possibility that the medical waiver 
might not be accepted by the destination country.
Because requirements and recommendations might change, 
all travelers should seek up-to-date information before travel 
from health departments, CDC, and WHO. Travel agencies, 
international airlines, or shipping lines also might have up-
to-date information. Updated information on requirements 
and recommendations for vaccination are available at http://
wwwnc.cdc.gov/travel.
TABLE 2. Contraindications and precautions to yellow fever vaccine administration
Contraindications Precautions
Allergy to vaccine component Age 6–8 months
Age less than 6 months Age ≥60 years†
Symptomatic HIV infection or CD4+ T-lymphocytes <200/mm3 (or <15% of total in 
children aged <6 years)*
Asymptomatic HIV infection and CD4+ T-lymphocytes 200–499/mm3 
(or 15%–24% of total in children aged <6 years)*
Thymus disorder associated with abnormal immune function† Pregnancy
Primary immunodeficiencies Breastfeeding
Malignant neoplasms
Transplantation
Immunosuppressive and immunomodulatory therapies†
* Symptoms of HIV have been classified (Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected 
adults and adolescents; US Department of Health and Human Services; 2008. Available at http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem= 
Guidelines&Search=Off&GuidelineID=7&ClassID=1. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the 
Use of Antiretroviral Agents in Pediatric HIV Infection; 2009. Available at http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf.)
† New contraindication or precaution since the ACIP’s recommendations for the use of yellow fever vaccine were published in 2002 (CDC. Yellow fever vaccine: recom-
mendations of the Advisory Committee on Immunizations Practices: MMWR 2002;51[No. RR-17]).
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Administration of Yellow Fever 
Vaccine
Dosage and Administration
For persons of all ages for whom vaccination is indicated, 
a single subcutaneous injection of 0.5 mL of reconstituted 
vaccine is used. According to the package insert, the vaccine 
needs to be administered within 1 hour of reconstitution (71). 
Once reconstituted, a multidose vial should be maintained at 
35°F–46°F (2°C–8°C), and the remaining doses should be 
used or discarded within 1 hour.
Although limited data suggest YF vaccine might retain its 
potency following the expiration date (126), the package 
insert states that the vaccine should not be used after its expi-
ration date. According to ACIP’s General Recommendations 
on Immunization, a dose of an expired vaccine should not 
be counted as valid, and the dose should be repeated with 
a nonexpired vaccine following a 28-day interval (127). For 
more guidance on the inadvertent administration of an expired 
vaccine, health-care providers should contact the vaccine 
manufacturer.
If the vaccine is administered inadvertently via the intra-
muscular route, the response to vaccine probably will not 
be affected. Repeating doses of vaccine administered by the 
intramuscular route rather than by the subcutaneous route is 
not necessary (127).
Anaphylaxis has been reported to occur in persons with no 
history of reactions to the components of the vaccine. Given 
this, all persons should be observed for at least 15 minutes 
following the administration of the vaccine, and epinephrine 
FIGURE 3. International Certificate of Vaccination or Prophylaxis (ICVP)*
Source: Brunette GW, Kozarsky PE, Magill AJ, Shlim DR, Whatley AD, eds. CDC health information for international travel 2010. Atlanta. GA: US Department of Health 
and Human Services, Public Health Service, CDC; 2009.
* International Health Regulations allow countries to require proof of yellow fever vaccination for entry and from travelers arriving from certain countries to prevent 
importation and indigenous transmission of yellow fever vaccine. As proof of vaccination, vaccinees should receive a completed ICVP, validated (stamped and signed) 
with the stamp of the center where the vaccine was administered.
INTERNATIONAL CERTIFICATE OF VACCINATION OR PROPHYLAXIS
Certificat international de vaccination ou de prophylaxie
This is to certify that         
Nous certitions que  (name - nom) (date of birth - né(e) le) (sex - de sexe) (nationality - et de nationalité)
  whose signature follows   
(national identification document, if applicable - document d’identification nationale, le cas échéant) dont la signature suit
has on the date indicated been vaccinated or received prophylaxis against   in accordance with the International Health Regulations.
a éré vacciné(e) ou a reçu une prophylaxie à la date indiguée (name of disease or condition - nom de la maladie ou de l’affection) conformément au Règlement sanitaire international.
Vaccine or prophylaxis
Vaccine ou agent
prophylactique
Date Signature and professional 
status of supervising 
clinician
Signature et litre du
professopnel de santé
responsable
Manufacturer and batch no.
of vaccine or prophylaxis
Fabricant du vaccin ou de
l’agent prophlactique et
numéro du lot
Certificate valid
from:
until:
Certificat valable
à partie du:
jusqu’au:
Official stamp of the administering center
Cachet officiel du centre habilité
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injection (1:1,000) should be readily available in case of a seri-
ous allergic reaction. Furthermore, because reactions have been 
delayed up to several hours following YF vaccine, all patients 
should be advised of signs and symptoms of an allergic reac-
tion (e.g., urticaria, angioedema, rash, dyspnea, bronchospasm, 
pharyngeal edema, wheezing, and throat tightness). In addi-
tion, vaccinated persons should be advised to seek immediate 
medical care if any symptoms of an allergic reaction develop 
following vaccination.
Transfusion-related transmission of yellow fever vaccine 
virus has been documented among persons receiving blood 
products that were collected from recently vaccinated persons 
(75). Blood donation centers should screen blood donors to 
determine if they received a yellow fever vaccine within the 
preceding 2 weeks and defer these donors. However, practices 
vary between blood collection centers, and questions about 
vaccination history might not be asked routinely. Therefore, 
health-care providers should advise persons to defer blood 
donation for 2 weeks after receiving YF vaccine.
Booster Doses
IHRs require revaccination at intervals of 10 years to boost 
antibody titer. Evidence from multiple studies demonstrates 
that YF vaccine immunity persists for many decades and might 
provide life-long protection (79,80,128,129).
To minimize the occurrence of adverse events and optimize 
the immune response, efforts should be taken to observe a 
10-year interval between YF vaccine doses. However, limited 
data suggest that revaccination occurring <10 years after the 
previous dose does not increase the risk for adverse events 
(74), particularly as serious adverse events occur primarily 
after the initial vaccination of YF vaccine. Although the level 
of YFV-specific antibodies formed following revaccination 
appears to be correlated inversely to the amount of preexisting 
antibodies (130), no data suggest that earlier revaccination will 
have a negative impact on seroprotection. If the date of the 
most recent vaccination cannot be ascertained, and the patient 
requires vaccination, a booster dose should be administered.
Simultaneous Administration of other 
Vaccines or Drugs
Determination of whether to administer YF vaccine and 
other immunobiologics simultaneously (i.e., administration on 
the same day but at a different injection site) should be made 
on the basis of convenience to the traveler in completing the 
FIGURE 4. Medical contraindication section of the International Certificate of Vaccination or Prophylaxis (ICVP)*
Source: Brunette GW, Kozarsky PE, Magill AJ, Shlim DR, Whatley AD, eds. CDC health information for international travel 2010. Atlanta. GA: US Department of Health 
and Human Services, Public Health Service, CDC; 2009.
* A health-care provider who identifies a medical contraindication to yellow fever vaccination and wants to issue a medical waiver should fill out and sign the Medical 
Contraindications to Vaccination section of the ICVP. The health-care provider also should give the traveler a signed and dated exemption letter.
MEDICAL CONTRAINDICATION TO VACCINATION
Contre-indication médicale à la vaccination
This is to certify that immunication against
Je soussigné(e) certifie que ia vaccination contre
  for
(Name of disease - Nom de la maladie) pour
  is medically
(Name of traveler - Nom du voyageur) est medicalement
contraindicated because of the following conditions:
contre-indiquée pour les raisons suivantes:
 
 
 
  
 (Signature and address of physician)
 (Signature et adresse du médecin)
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desired vaccinations before travel and on information regarding 
possible immune interference.
No evidence exists that inactivated vaccines and YF vaccine 
interfere with the immune response to the vaccine. Therefore, 
inactivated vaccines can be administered either simultaneously 
or at any time before or after YF vaccination (127). YF vaccine 
should be administered either simultaneously or 30 days apart 
from other live viral vaccines because the immune response to 
one live virus vaccine might be impaired if administered within 
30 days of another live-virus vaccine (131,132). Limited data 
suggest that the serologic response to YF vaccine is not inhib-
ited by administration of measles vaccine nonsimultaneously 
within 30 days of YF vaccine administration (133). However, 
the serologic response to measles vaccine was not assessed in 
this study. Oral Ty21a typhoid vaccine can be administered 
simultaneously or at any interval before or after YF vaccine 
attributable to the different routes of administration (34).
Vaccines that have been administered simultaneously with 
YF vaccine without interfering in the immune response to the 
vaccines or resulting in unusual safety profiles include Bacillius 
Calmette-Guerin (134), diphtheria (135,136), hepatitis A 
(137,138), hepatitis B (139), influenza (140), measles (133), 
meningococcal (Menomune) (141), pertussis (136), polio 
(135), smallpox (136,142), tetanus (135,136), and typhoid 
(both injectable [138] and oral [143,144]). No data exist 
regarding possible interference between YF vaccine and rabies, 
human papillomavirus, Japanese encephalitis, live attenuated 
influenza, or varicella virus vaccines (145).
Studies of persons administered YF vaccine and immune 
globulin simultaneously found no alteration of the immuno-
logic response to YF vaccine when compared with controls (i.e., 
YF vaccine alone) (146,147). Although chloroquine inhibits 
replication of YFV in vitro, it does not affect antibody responses 
to YF vaccine adversely among persons receiving antimalarial 
prophylaxis (148).
No data exist for YF vaccine and the potential suppression 
of the tuberculin skin test (TST) response. However, because 
the use of live attenuated measles vaccine theoretically can 
suppress TST reactivity resulting in a false-negative reaction, 
ACIP’s General Recommendations on Immunization suggest 
that TST should be administered at the same time as YF vac-
cine or 4 weeks after receipt of YF vaccine (127). Alternatively, 
TST screening can be performed and read before administer-
ing YF vaccine. However, if YF vaccine has been administered 
recently, TST screening should be delayed for at least 4 weeks 
after vaccination (127).
Contraindications
Allergy to Vaccine Components
YF vaccine is contraindicated for persons with a history of 
hypersensitivity to any of the vaccine components, including 
eggs, egg products, chicken proteins, or gelatin. The stopper 
used in vials of vaccine also contains dry latex rubber, which 
might cause an allergic reaction (71).
According to the manufacturer, persons who are able to 
eat eggs or egg products may receive the vaccine. However, 
potential hypersensitivity reactions might occur in persons 
with a history of minor reactions to eggs. For egg-sensitive 
persons, a scratch test or intradermal test can be performed 
before administering the vaccine to check for reactivity. If a 
person has a severe egg-sensitivity or has a positive skin test 
to the vaccine, but the vaccination is recommended because 
of their travel destination-specific risk, desensitization can be 
performed under direct supervision of a physician experienced 
in the management of anaphylaxis. The desensitization proce-
dure is detailed in the product insert (71).
Given the risk for anaphylaxis, even among persons with 
no history of reactions to components of the vaccine, all 
persons should be observed for at least 15 minutes following 
the administration of the vaccine, and epinephrine (1:1,000) 
should be readily available in case of a serious allergic reac-
tion. Vaccinated persons should be advised of symptoms of 
an allergic reaction and should be advised to seek immediate 
medical care if any symptoms of an allergic reaction develop 
following vaccination.
Infants Aged <6 Months
YF vaccine is contraindicated for infants aged <6 months. 
This contraindication was instituted in the late 1960s in 
response to a high rate of YEL-AND documented in vacci-
nated young infants (97). The mechanism of increased neu-
rovirulence in infants is unknown but might be attributable 
to the immaturity of the blood-brain barrier, higher or more 
prolonged viremia, or immune system immaturity.
Altered Immune Status
thymus Disorder
YF vaccine is contraindicated for persons with a thymus 
disorder that is associated with abnormal immune cell function 
(e.g., thymoma or myasthenia gravis) (149). Four (17%) of 
the initial 23 YEL-AVD reported cases were noted to occur in 
persons who had had thymectomies performed for thymomas 
(117). In 2003, thymus disorder was added to the YF vaccine 
package insert as a contraindication. To date, no evidence has 
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been identified of immune dysfunction or increased risk for YF 
vaccine-associated serious adverse events in persons who have 
undergone incidental surgical removal of their thymus or have 
had indirect radiation therapy in the distant past. Therefore, 
YF vaccine can be administered, if indicated based on their 
destination-specific YF risk, in persons who underwent inci-
dental surgical removal of the thymus or have a remote history 
of radiation therapy to the thymus.
AIDS and HIV Infection with Severe Immune 
Suppression
YF vaccine is contraindicated for persons with acquired 
immunodeficiency syndrome (AIDS) or other clinical mani-
festations of HIV (150,151), including persons with CD4 
counts <200 per mm3 or <15% of total lymphocytes for 
children aged <6 years. This recommendation is based on a 
theoretic increased risk for encephalitis in this population. 
One fatal YEL-AND case has been reported in a person with 
a previously undiagnosed HIV infection and a CD4 count 
of 108 cells/mm3 who was vaccinated with YF vaccine (98). 
No large prospective, randomized trials have been performed 
to address the safety and efficacy of YF vaccine among this 
group adequately. Several retrospective and prospective stud-
ies that included a total of approximately 450 HIV-infected 
persons who received YF vaccine reported no additional seri-
ous adverse events. However, these studies included a limited 
subset of adults (n = 10) with a CD4 counts <200 per mm3 
(84–87,98,152–155).
If travel to an area in which YF is endemic cannot be avoided 
in a person with severe immune suppression based on CD4 
counts (<200 per mm3 or <15% total) or symptomatic HIV, a 
medical waiver should be provided, and counseling on protec-
tive measures against mosquito bites should be emphasized. 
(See Precautions for other HIV-infected persons not meeting 
these criteria.)
Immunodeficiencies other than thymus 
Disorder or HIV Infection
YF vaccine is contraindicated for persons with primary 
immunodeficiencies, malignant neoplasms, and transplanta-
tion (127). Although no data exist on the use of YF vaccine 
in these persons, they are presumed to have an increased risk 
for YF vaccine-associated serious adverse events. More specific 
information on primary immunodeficiencies for which the use 
of live viral vaccines, such as YF vaccine, is contraindicated 
will be published (127). In general, solid organ transplant or 
hematopoietic stem cell transplant recipients within 2 years 
of transplantation, or persons whose transplants occurred >2 
years ago but who are still taking immunosuppressive drugs, are 
considered to be immunosuppressed (156). Live viral vaccines 
should be deferred in persons with a history of malignant neo-
plasm or transplantation until immune function has improved 
substantially. This is best determined by a physician who is 
familiar with the patient and the patient’s underlying medical 
condition and treatments in consultation with a YF vaccination 
center. If a person with an immunodeficiency cannot avoid 
travel to an area in which YF is endemic, a medical waiver 
should be provided, and counseling on protective measures 
against mosquito bites should be emphasized.
Immunosuppressive and 
Immunomodulatory therapies
YF vaccine is contraindicated for person whose immunologic 
response is either suppressed or modulated by current or recent 
radiation therapies or drugs. Drugs with known immunosup-
pressive or immunomodulatory properties include high-dose 
systemic corticosteroids, alkylating drugs, antimetabolites, 
TNF-α inhibitors (e.g., etanercept), IL-1 blocking agent (e.g., 
anakinra), and other monoclonal antibodies targeting immune 
cells (e.g., rituximab, alemtuzumab). No specific data exist 
on the use of YF vaccine in persons receiving these therapies. 
However, these persons are presumed to be at an increased risk 
for YF vaccine-associated serious adverse events, and the use 
of live attenuated vaccines in these persons is contraindicated 
according to the package insert for most of these therapies 
(127).
Although the immunosuppressive effects of corticosteroids 
can vary, a dose of either ≥2 mg/kg of body weight or a total 
≥20 mg/day of prednisone or its equivalent for persons who 
weigh >10 kg when administered for ≥2 weeks is considered 
sufficiently immunosuppressive to contraindicate the use 
of live attenuated vaccines (127). Corticosteroids are not a 
contraindication when administration is under any of the 
following circumstances: short-term (i.e., <2 weeks); a low-
to-moderate dose (<20 mg of prednisone or its equivalent per 
day); long-term, alternate-day treatment with short-acting 
preparations; maintenance physiologic doses (replacement 
therapy); or administered topically (skin or eyes), inhaled, or 
by intra-articular, bursal, or tendon injection (127).
Administration of live viral vaccines should be deferred in 
persons who have discontinued these therapies until immune 
function has improved. This is best determined by a physician 
who is familiar with the patient’s underlying medical conditions 
and by the patient’s pharmacist, who can assist in determining 
the specific half-lives of the immunosuppressive drugs and 
the potential duration of immune suppression. If someone 
receiving immunosuppressive or immunomodulatory therapies 
cannot avoid travel to an area in which YF is endemic , a medi-
cal waiver should be provided, and counseling on protective 
measures against mosquito bites should be emphasized.
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Precautions
Infants Aged 6–8 Months
Age 6–8 months is a precaution for YF vaccine administra-
tion. In infants aged <6 months, the rates of YEL-AND are 
substantially elevated (50–400 cases per 100,000 infants vac-
cinated) (96,106). Two cases of YEL-AND have been reported 
among infants aged 6–8 months (96). By age 9 months, the risk 
for YEL-AND is believed to be substantially lower. In general, 
whenever possible, travel of children aged 6–8 months to coun-
tries in which YF is endemic should be postponed or avoided. 
If travel is unavoidable, the decision of whether to vaccinate 
these infants needs to balance the risks for YFV exposure with 
the risk for adverse events following vaccination.
Adults Aged ≥60 Years
Age ≥60 years is a precaution for YF vaccine administra-
tion, particularly if the first dose of the YF vaccine is to be 
administered. A recent analysis of adverse events reported to 
VAERS during 2000–2006 indicates that persons aged ≥60 
years are at increased risk for any serious adverse events after 
vaccination, compared with younger persons (89). The rate 
of serious adverse events in persons aged ≥60 years was 8.3 
events per 100,000 doses distributed compared with 4.7 events 
per 100,000 doses distributed for all YF vaccine recipients. 
This reinforces findings from VAERS data from 1990–1998 
that reported the rate of serious adverse events was 7.5 times 
higher in persons aged ≥60 years than in the reference group 
(persons aged 19–29 years) (107). The risk for YEL-AND 
and YEL-AVD also are increased in this age group, at 1.8 and 
1.4 reported cases per 100,000 doses distributed, respectively, 
compared with 0.8 and 0.4 reported cases per 100,000 doses 
distributed for all YF vaccine recipients. Given that YEL-AND 
and YEL-AVD are seen almost exclusively in primary vaccine 
recipients, caution should be exercised with older travelers 
who might be receiving YF vaccine for the first time. If travel 
is unavoidable, the decision to vaccinate travelers aged ≥60 
years needs to weigh the risks and benefits of the vaccination 
in the context of their destination-specific risk for exposure 
to YFV.
Asymptomatic HIV Infection with 
Moderate Immune Suppression
Asymptomatic HIV infection with moderate immune sup-
pression (i.e., CD4 counts of 200–499 per mm3 for persons 
aged ≥6 years or 15%–24% of total lymphocytes for children 
aged <6 years) is a precaution for YF vaccine administration. 
Large prospective randomized trials have not been performed 
to address the safety and efficacy of YF vaccine adequately 
among this group. Several retrospective and prospective studies 
including approximately 450 persons infected with HIV have 
reported no serious adverse events among patients considered 
moderately immunosuppressed based on the their CD4 counts 
(84–87,152–155).
HIV infection has been associated with a reduced immuno-
logic response to a number of inactivated and live-attenuated 
vaccines, including YF vaccine (84). In a recent retrospective 
cohort study, 65 (83%) of 78 HIV-infected persons developed 
specific antibodies against YFV in the first year after vaccina-
tion; however, this was significantly lower than vaccinated 
persons without HIV infection (97% [64/66]; p=0.01) (86). 
Among HIV-infected infants in developing nations, only three 
(17%) of 18 developed YFV-specific neutralizing antibodies 
within 10 months of vaccination compared with 42 (74%) of 
57 HIV-uninfected controls matched for age and nutritional 
status (87). The mechanisms for the diminished immune 
response in HIV-infected persons are uncertain but appear to 
be correlated with HIV RNA levels and CD4 counts. Because 
vaccination of asymptomatic HIV-infected persons might be 
less effective than that for persons not infected with HIV, 
measurement of their neutralizing antibody response to vac-
cination should be considered before travel. Health-care pro-
viders should contact the appropriate state health department 
or CDC (at telephone 1-970 221-6400) to discuss serologic 
testing further.
For HIV-infected persons who experience immune recon-
stitution in response to antiretroviral therapy, their current 
CD4 count and symptoms of HIV infection (if stable over 
3 month time period) rather than a CD4 count nadir and a 
history of prior opportunistic infections/symptomatic HIV 
should be used to categorize their HIV status (156). Of note, 
one YEL-AVD case was reported in a person determined to 
have a genetic polymorphisms in chemokine receptor CCR5 
(118). Consequently, concern has been raised that despite 
having adequate immune function, persons with HIV infec-
tion who are receiving an antiretroviral regimen containing a 
CCR5-receptor antagonist could be at increased risk for adverse 
events after YF vaccination (157). Further research is needed 
to address this concern.
If an asymptomatic HIV-infected person with moderate 
immune suppression is traveling to an area in which YF is 
endemic, vaccination can be considered. Vaccinated persons 
should be monitored closely after vaccination for evidence of 
adverse events. If an adverse event occurs, a VAERS report 
should be filed, and the state health department or CDC should 
be notified to obtain technical support and assistance with 
diagnostic testing. If international travel requirements rather 
than an increased risk for acquiring YFV infection are the only 
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reason to vaccinate HIV-infected persons, the person should be 
excused from vaccination and issued a medical waiver to fulfill 
health regulations. If an asymptomatic HIV-infected person 
has no evidence of immune suppression based on CD4 counts 
(CD4 count ≥500 per mm3 or ≥25% of total lymphocytes 
for children aged <6 years), YF vaccine can be administered, 
if recommended on the basis of their destination-specific YF 
risk. (See Contraindications for other HIV-infected persons 
not meeting these criteria.)
Pregnancy
Pregnancy is a precaution for YF vaccine administration, 
compared with most other live vaccines, which are contrain-
dicated in pregnancy. If travel is unavoidable, and the risks 
for YFV exposure are felt to outweigh the vaccination risks, 
a pregnant woman should be vaccinated. If the risks for 
vaccination are felt to outweigh the risks for YFV exposure, 
pregnant women should be issued a medical waiver to fulfill 
health regulations. Although no specific data are available, a 
woman should wait 4 weeks after receiving YF vaccine before 
conceiving. (See Vaccination of Women During Pregnancy 
and Breastfeeding.)
Breastfeeding
Breastfeeding is a precaution for YF vaccine administration. 
Two serious adverse events have been reported in exclusively 
breastfed infants whose mothers were vaccinated with YF vac-
cine (123; PHAC, unpublished data, 2008). Further research 
is needed to document the risk for potential vaccine exposure 
through breastfeeding. Until more information is available, 
YF vaccine should be avoided in breastfeeding women. 
However, when travel of nursing mothers to a YF endemic 
area cannot be avoided or postponed, these women should be 
vaccinated. (See Vaccination of Women During Pregnancy 
and Breastfeeding.)
Special Populations
Age
YF vaccine is approved for use in persons aged ≥9 months. 
The vaccine is contraindicated for infants aged <6 months. (See 
Contraindications for more information.) Age 6–8 months and 
adults aged ≥60 years are precautions for YF vaccine adminis-
tration. (See Precautions.)
Pregnancy
Limited data are available regarding the safety and immuno-
genicity of YF vaccine in pregnancy. Pregnancy is a precaution 
for YF vaccine administration. (See Vaccination of Women 
During Pregnancy and Breastfeeding and Precautions.)
Breastfeeding Women
Although no data are available on the immune response in 
breastfeeding mothers, no alteration to the immune response in 
these women are suspected. Limited data are available regarding 
the safety of YF vaccine in breastfed infants. Breastfeeding is 
a precaution for YF vaccine administration. (See Vaccination 
of Women During Pregnancy and Breastfeeding and 
Precautions.)
Altered Immune Status
The following conditions are a contraindication for YF vac-
cine administration: 1) thymus disorders associated with abnor-
mal immune cell function, 2) symptomatic HIV-infection or 
CD4+ T-lymphocyte values <200 per mm3 or <15% of total 
lymphocytes for children aged <6 years, 3) primary immuno-
deficiencies, 4) malignant neoplasms, 5) transplantation, and 
6) immune suppression or modulation attributable to current 
or recent radiation therapies or drugs. The following condi-
tion with altered immune status is a precaution for YF vaccine 
administration: asymptomatic HIV-infection with CD4+ 
T-lymphocyte values 200–499 per mm3 or 15%–24% of total 
lymphocytes for children aged < 6 years. (See Contraindications 
and Precautions.)
Complete details are not available regarding what medications 
the nine patients with reported YEL-AVD who had a history 
of autoimmune disease or diseases with potential autoimmune 
etiology were taking; these might have included immunosup-
pressive medications. Four of the nine patients were aged >60 
years, including two who also had a history of thymectomy for 
thymoma (see YEL-AVD). Older age and history of thymoma 
are both risk factors for YEL-AVD. Nonetheless, the fact that 
nine (16%) of 57 persons with reported cases of YEL-AVD had 
a history of autoimmune disease is a concern and suggests that 
autoimmune disease, either by itself of in conjunction with 
other risk factors, including immunosuppressive medication, 
could increase the risk for YEL-AVD. Definitive data are lack-
ing to guide decision-making about YF vaccination in these 
patients. Health-care providers should consider the possibility 
of diminished immune function resulting from the autoim-
mune disease state itself and/or the medication used in deciding 
whether or not to administer YF vaccine to these patients.
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Reporting of Vaccine Adverse 
Events
Even if a causal relation to vaccination is not certain, all 
adverse events following receipt of vaccine that are thought 
to be clinically significant by health-care providers or vaccine 
recipients should be reported to VAERS at http://vaers.hhs.gov 
or by telephone at 1-800-822-7967. To promote better timeli-
ness and quality of safety data, secure web-based reporting is 
available and health-care providers are encouraged to report 
electronically at https://vaers.hhs.gov/esub/step1.
Surveillance to monitor, characterize, and quantify YF 
vaccine-specific adverse outcomes are ongoing. Because cur-
rent reporting mechanisms are strictly passive, detection of 
of YEL-AVD and YEL-AND in recently vaccinated persons 
who experience new symptoms largely depends on health-
care providers being familiar with these conditions and with 
reporting requirements. An education program regarding the 
vaccine and possible serious adverse events is being developed 
and will be made available to all health-care providers by fall 
2010 through CDC’s Travelers’ Health website. State health 
departments are encouraged to incorporate requirements for 
completion of these programs into their certification and 
recertification processes for issuance of YF vaccination stamps 
to health-care providers.
Future Research
Research focusing on suspected risk factors for serious adverse 
events or suboptimal response to YF vaccine for which few 
or no data exist should be designed and implemented. This 
should include HIV, immunosuppressive diseases, autoim-
mune diseases, and use of immunosuppressive and immuno-
modulatory drugs. Ethical considerations might limit these to 
observational studies. If possible, studies geared to collecting 
population-based data would be the most useful, though also 
the most difficult to implement. Further research also is needed 
to determine if YF vaccine virus is present in breast milk and 
the exact route of transmission involved (e.g., ingested milk 
or blood).
Studies addressing the duration of immune response to the 
vaccine, in particular the duration of IgM antibodies following 
vaccination and the duration of protective antibody levels, are 
warranted. These studies would help resolve issues related to 
possible YF disease in vaccinated travelers as well as provide 
updated evidence on the dosing interval needed for booster 
doses of the vaccine. Finally, studies examining the immune 
response to an inactivated yellow fever vaccine are underway. 
If successful, the inactivated vaccine potentially could be 
administered to persons with contraindications to the use of 
a live viral vaccine.
Additional Information
Information about YF for travelers and health-care providers 
has been published previously (34). Additional information 
about YF is available at http://www.cdc.gov/ncidod/dvbid/
yellowfever/index.html. Additional licensure information for 
the YF vaccine that is approved in the United States is avail-
able at http://www.fda.gov/BiologicsBloodVaccines/Vaccines/
ApprovedProducts/ucm094074.htm.
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